Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. 
Ingested formula components arrive intact to intestinal villi, thanks to the protection of the enteric layer and from there go into the bloodstream to be selectively incorporated by the cells via various means of cellular transport, depending on the size of molecules such components. Large molecules are incorporated by endocytosis and the smaller molecules are incorporated by simple diffusion or diffusion provided by receptor proteins, as appropriate.
The useful parts of the cell extracts are recycled and used in cells. The parts that are not useful are eliminated and expelled outside the cell.
The incorporation of the various components to the corresponding cell tissues is facilitated by the empathy developed by Biocell Laboratories between these components and the receptor proteins on the cell membrane surface.